Clinical Trial Update: Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease [Phase 3]

View source ↗

Summary

An extended Phase 3 evaluation of PROCHYMAL adult human stem cells for treatment-resistant Crohn's disease has completed, according to Mesoblast.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• PROCHYMAL (allogeneic mesenchymal stem cells)

Snippet

Sponsor: Mesoblast, Inc. | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED